Trial of Lixisenatide in Early Parkinson’s Disease
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [104]
In the citing paper
“The results showed that liraglutide had a modest positive effect on improving motor function and performed well in terms of safety and tolerability, although there were some manageable gastrointestinal side effects.432”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [432]
In the citing paper
“Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinson’s disease (15, 53).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [53]
In the citing paper
“In Parkinson's disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo,53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.55”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [54]
In the citing paper
“In addition, lixisenatide slowed motor decline in a phase 2 randomized clinical trial in patients with early Parkinson disease.33”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Self-citationSystematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationTrial of Prasinezumab in Early-Stage Parkinson’s Disease
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202867 · Cited by 421
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“432 The study emphasizes the need for further research into the potential bene fi ts and risks of liraglutide in patients at different stages of PD. 432 GLP-1RAs and addictive disorders .”
BackgroundTanner, C. M., & Ostrem, J. L. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2401857 · Cited by 382
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Positive results, principally the halting of disease progression, were reported in trials of exenatide twice daily 136 , exenatide once weekly 137 and lixisenatide once daily 138 .”
Parkinson disease therapy: current strategies and future research priorities
Stocchi, F., Bravi, D., Emmi, A., & Antonini, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01034-x · Cited by 204
“For example, glucagon-like peptide 1 receptor agonists that are used to treat diabetes have shown promise in patients with PD, highlighting a potential role for brain insulin signalling and insulin receptors in this condition 133,134 .”
Metadata
- Authors
- Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M., Ferrier, V., Foubert-Samier, A., Frismand-Kryloff, S., Geny, C., Georget, A., Germain, C., Grimaldi, S., Hardy, C., Hopes, L., Krystkowiak, P., Laurens, B., Lefaucheur, R., Mariani, L.-L., Marques, A., Marse, C., Ory-Magne, F., Rigalleau, V., Salhi, H., Saubion, A., Stott, S. R. W., Thalamas, C., Thiriez, C., Tir, M., Wyse, R. K., Benard, A., & Rascol, O.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- French Clinical Research Network for Parkinson’s Disease and Movement Disorders (NS-Park/F-CRIN), France
- Université Côte d'Azur (FR)
- Inserm (FR)
- Clinical Investigation Center CIC1436 and Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France
- Université de Bordeaux (FR)
- French Clinical Research Infrastructure Network (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Cure Parkinson’s, London, UK
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Service d’Information Médicale, Clinical Epidemiology Unit (USMR), CHU Bordeaux, F-33000 Bordeaux, France
- ORCID
- Meissner, Wassilios G.
- Maltête, David
- Derkinderen, Pascal
- Houéto, Jean-Luc
- Anheim, Mathieu
- Boraud, Thomas
- Carrière, Nicolas
- Colin, Olivier
- Corvol, Jean-Christophe
- Damier, Philippe
- Dellapina, Estelle
- Devos, David
- Drapier, Sophie
- Fabbri, Margherita
- Grimaldi, Stéphane
- Hopes, Lucie
- Laurens, Brice
- Lefaucheur, Romain
- Mariani, Louise-Laure
- Rigalleau, Vincent
- Stott, Simon R. W.
- Thalamas, Claire
- Thiriez, Claire
- Tir, Mélissa
- Wyse, Richard K.
- Rascol, Olivier
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-04
- Volume
- 390
- Issue
- 13
- Pages
- 1176-1185
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4393852482
- Cited by
- 369
- References
- 30
- Citations by year
- 2026: 125 · 2025: 160 · 2024: 83
- FWCI
- 97.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Cure Parkinson’s
- French Ministry of Health - PHRC-N
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- lixisenatide, Parkinson's disease, GLP-1 receptor agonists, early-stage Parkinson's disease, MDS-UPDRS III, levodopa equivalent daily dose, nausea, neuroprotection, off-medication state, washout period, subcutaneous administration, anti-inflammatory therapy, neurodegeneration, neuroinflammation
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Motor Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Antiparkinson Agents, Double-Blind Method, Persons with Disabilities, Humans, Injections, Subcutaneous, Parkinson Disease, Peptides, Treatment Outcome, Disease Progression, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial of Lixisenatide in Early Parkinson’s Disease. https://app.cochat.ai/papers/10.1056/nejmoa2312323
- The paper
- Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., . . . Rascol, O. (2024). Trial of Lixisenatide in Early Parkinson’s Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2312323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.